Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
November 01 2023 - 8:00AM
Business Wire
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle
disease biopharmaceutical company, today announced that the Company
will present the results of nonclinical studies of EDG-7500 at the
American Heart Association’s (AHA) Scientific Sessions 2023 being
held in Philadelphia from November 11 - 13. EDG-7500 is a
first-in-class oral, selective, cardiac sarcomere modulator,
specifically designed to slow early contraction velocity and
address impaired cardiac relaxation associated with hypertrophic
cardiomyopathy (HCM) and other diseases of diastolic
dysfunction.
Details of the Rapid Fire Oral Presentation:
Title: EDG-7500, a Novel Cardiac Sarcomere Regulator That
Preserves Intrinsic Myosin-Motor Function, Improves Cardiac
Function and Reserve in a Minipig Model of Hypertrophic
Cardiomyopathy Session: The Pharmacologic Management of
Heart Failure: Beyond Guidelines and Paradigms Date and
Time: Monday, November 13, 2023, 2:20 – 2:25 pm ET
Details of the Scientific Poster Presentation:
Title: Cardiac Effects of EDG-7500, a Novel Cardiac
Sarcomere Regulator: In Vitro and In Vivo Evidence for Slowing
Isovolumic Contraction and Improved Ventricular Compliance (Board
#2163) Session: Bench to Bedside: Novel Therapeutic
Approaches in Heart Failure Date and Time: Saturday,
November 11, 2023, 11:30 am – 12:45 pm ET
The AHA Scientific Sessions’ program is available here. The
Edgewise presentation and poster will be available on the Edgewise
website when they are presented.
About EDG-7500 for Hypertrophic Cardiomyopathy
EDG-7500 is a first-in-class oral, selective, cardiac sarcomere
modulator produced by the Company’s robust discovery platform. The
compound is specifically designed to slow early contraction
velocity and address impaired cardiac relaxation associated with
HCM and other diseases of diastolic dysfunction. The Company is
enrolling a Phase 1 randomized, double-blind, placebo-controlled,
single and multiple ascending dose study of EDG-7500 evaluating
safety, tolerability, pharmacokinetics and pharmacodynamics in
healthy adults. To learn more about this study (NCT06011317), go to
clinicaltrials.gov. The Company is also planning to begin a Phase
1b study of EDG-7500 in individuals with obstructive HCM in the
first half of 2024.
About Hypertrophic Cardiomyopathy
HCM is the most common form of genetic heart disease with an
estimated prevalence of as many as 700,000 people in the United
States. The molecular underpinnings of HCM lead to abnormal cardiac
sarcomeric protein function that eventually results in excessive
contraction of the heart muscle, referred to as hypercontractility.
Over time, hypercontractility increases the thickness (hypertrophy)
of the heart’s left ventricular (LV) walls – the heart’s primary
pumping chamber. Progressive hypertrophy eventually leads to a
thick and stiff LV thereby reducing its ability to fill with blood
during relaxation (diastole) and pump blood during contraction
(systole). A decreased volume of blood entering and leaving the LV
causes shortness of breath, rapid heartbeat, chest pain,
unexplained fatigue, dizziness, and syncope (loss of
consciousness), which together cause HCM patients to become limited
in their ability to perform activities of daily living. HCM can be
diagnosed at any age; disease progression increases the risk of
heart failure, stroke and atrial fibrillation. Despite advancements
in the development of therapies to treat HCM, there is currently a
significant unmet need for additional therapies.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for
muscular dystrophies and serious cardiac conditions. The company’s
deep expertise in muscle physiology is driving a new generation of
first-in-class therapeutics. EDG-5506 is an orally administered
skeletal myosin inhibitor in clinical trials in patients with
Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as
McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel
cardiac sarcomere modulator for the treatment of HCM and other
disorders of cardiac diastolic dysfunction. The entire team at
Edgewise is dedicated to our mission: changing the lives of
patients and families affected by serious muscle diseases. To learn
more, go to: www.edgewisetx.com or follow us on LinkedIn, X
(formerly Twitter), Facebook, Instagram and Threads.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference into this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101877319/en/
Investors & Media Michael Carruthers Chief Financial
Officer ir@edgewisetx.com
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From May 2024 to Jun 2024
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Jun 2023 to Jun 2024